J Sule, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (42.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.6% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $5,464, more than ten times the $285 reported in 2019.
Across 142 payments — averaging $76.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Boston Scientific$1K
- Procept Biorobotics Corporation$1K
- Urogen Pharma, Inc.$506
- Coloplast$226
- Pfizer$180
- plus $1K from 23 others
What the payments were for
- Travel & lodging$2,49423%
- Food & beverage$3,75235%
- Education$4,57542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $6,670 |
| Boston Scientific | 31 | $1,072 |
| Procept Biorobotics Corporation | 14 | $1,013 |
| Urogen Pharma, Inc. | 8 | $506 |
| Coloplast | 11 | $226 |
| Pfizer | 9 | $180 |
| AbbVie(2 entities) | 7 | $155 |
| Urovant Sciences Inc | 9 | $135 |
| Astellas Pharma US Inc | 8 | $124 |
| Medtronic(2 entities) | 2 | $102 |
| Sumitomo Pharma America, Inc. | 5 | $85 |
| Myovant Sciences Inc. | 4 | $71 |
| Microline Surgical Inc | 1 | $69 |
| Uroviu Corporation | 2 | $45 |
| Valencia Technologies Corporation | 1 | $42 |
| Endo USA, Inc. | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Laborie Medical Technologies Corp. | 2 | $33 |
| Johnson & Johnson | 1 | $32 |
| Merck | 1 | $29 |
| Braintree Laboratories, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$4,500
- Da Vinci Surgical System$2,046
- AquaBeam Robotic System$558
- JELMYTO$270
How this compares
$10,822 in reported general payments places this provider in the 75th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $10,890 |
| Testosterone | 13 | $3,034 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,837 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $2,003 |
| Tamsulosin Hcl | 125 | $1,546 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $782 |
| Finasteride | 53 | $773 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 38 | $533 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $279 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $239 |
| Cephalexin | 39 | $173 |
| Ondansetron OdtOndansetron | 19 | $127 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $96 |
| Levofloxacin | 21 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $124 | $10,89015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 96 urology providers in Utah.
Other urology in Nephi
- Steven GangeSlc$1.5M
- William BrantSalt Lake City$290K
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Jeffrey SparenborgProvo$37K
- Daniel SimonRiverton$33K
- Stewart LandauAmerican Fork$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.